Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Clinical Efficacy of Anti-Tigitmab BAT6005 Injection in Patients with Advanced Malignant Solid Tumors

NCT05116709 is registered in ClinicalTrials.gov with Bio-Thera Solutions as lead sponsor.

NCT NCT05116709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05116709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Clinical Efficacy of Anti-Tigitmab BAT6005 Injection in Patients with Advanced Malignant Solid Tumors
Lead sponsor
Bio-Thera Solutions
Phase
Phase 1
Overall status
Completed
Start date
November 12, 2021
Completion date
September 23, 2024
Enrollment
28 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic solid tumors